FAM3D is a protein mainly expressed in the gastrointestinal tract, but also detectable in vascular endothelial cells. It is known to worsen intestinal inflammation by recruiting neutrophils, but its ...

Focal adhesion kinase (FAK), a key mediator of cell adhesion and migration, is frequently upregulated in glioblastoma (GBM), where its activity has been associated with increased tumor invasiveness ...

Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, ...

To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there ...

Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and ...

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of psychiatric and neurological disorders.

Ribocure Pharmaceuticals AB, a subsidiary of Suzhou Ribo Life Science Co. Ltd., and Madrigal Pharmaceuticals Inc. have achieved the first drug candidate nomination within their siRNA partnership.

Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

With more and more approved products, cell and gene therapies (CGTs) are moving from the initial stronghold in academic medical centers, and these complex biologics are now available across a wider ...

Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions.

As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug ...